AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 251 min read$PHVS

Monges Viviane sold $396K of PHVS

Monges Viviane sold 11,969 shares of Pharvaris N.V. (PHVS) at $33.05 ($0.40M total) on 2026-09-23.

Original reporting
SEC EDGAR · Monges Viviane
Published Sep 25, 2026, 5:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 5:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
low confidence
Mentioned
$PHVS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The director's reduction in holdings is modest and unlikely to affect market perception.

02

Market read

Primary relevance is to traders monitoring insider activity; broader market impact is negligible.

03

What to watch

Potential upcoming dilution or financing events not disclosed in this filing.

Relevance 4/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filings disclose insider transactions; this is the first public report of this sale.

Company-level read

Ticker impact

$PHVSNeutralLow confidence
Context

Director Viviane Monges sold 11,969 shares for $395,524, reducing her stake to 5,500 shares.

Expected impact

Minimal impact; price may dip slightly on short-term supply pressure.

Evidence & confidence

Sale size is under $1M and represents a small portion of total shares; no broader market implications.

Market effects

Sector

None; the transaction is company‑specific.

Regional

No regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could signal insider concern, but size is too small to warrant a contrarian short.

Key entities

  • Company
    Pharvaris N.V.

    Biotech firm listed on Nasdaq under ticker PHVS.

  • Insider
    Viviane Monges

    Director of Pharvaris N.V.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHVS insider trading history →

Related articles

SEP 12
$BCRXHigh

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

stocktwits.com2 min
SEP 10
$PHVSMedAI 9/10

Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

investing.com3 min
SEP 9
$PHVSHighAI 8/10

Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.

rttnews.com2 min